- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Galecto GAAP EPS of -$2.60 | 2 | Seeking Alpha | ||
| GALECTO Aktie jetzt für 0€ handeln | |||||
| Di | Galecto, Inc.: Galecto Reports Second Quarter 2025 Operating and Financial Results | 43 | GlobeNewswire (Europe) | BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced... ► Artikel lesen | |
| Di | Galecto, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 20.06. | Galecto, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Galecto GAAP EPS of -$1.92 | 2 | Seeking Alpha | ||
| 08.05. | Galecto, Inc. Q1 Loss Declines | - | RTTNews | ||
| 08.05. | Galecto, Inc.: Galecto Reports First Quarter 2025 Operating and Financial Results | 156 | GlobeNewswire (Europe) | BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced... ► Artikel lesen | |
| 08.05. | Galecto, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.03. | Galecto GAAP EPS of -$18.53 misses by $2.62 | 4 | Seeking Alpha | ||
| 19.03. | Galecto, Inc.: Galecto Reports Full-Year 2024 Financial Results | 264 | GlobeNewswire (Europe) | Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
| 19.03. | Galecto, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 8 | SEC Filings | ||
| 19.03. | Galecto, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 01.11.24 | Galecto, Inc.: Galecto Reports Third Quarter 2024 Financial Results | 220 | GlobeNewswire (Europe) | - Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
| 28.08.24 | Galecto, Inc.: Galecto Announces Reverse Stock Split | 223 | GlobeNewswire (Europe) | BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,778 | +1,35 % | Evotecs Turnaround, Veganz Groups Rekordjahr, Pumas Neustart: Ihr Profit-Fahrplan durch die Marktwende! | Deutschlands Aktienmarkt zeigt sich im Juli 2025 extrem polarisiert. Während manche Schwergewichte straucheln glänzen andere mit Rekorden. Diese Volatilität speist sich aus Zinsängsten, disruptiven... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,320 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| MAINZ BIOMED | 1,410 | -2,76 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,645 | +3,77 % | Eli Lilly's obesity drug data lifts Viking Therapeutics stock | ||
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| ABIVAX | 60,30 | +0,50 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
| CELLECTAR BIOSCIENCES | 4,700 | -1,88 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| GALAPAGOS NV | 27,860 | -0,78 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; August 7, 2025, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,055 | -0,72 % | A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts | ||
| CENTOGENE | 0,180 | +91,49 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 7,730 | 0,00 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,034 | +14,21 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose... ► Artikel lesen | |
| CYTOKINETICS | 29,200 | -3,95 % | Cytokinetics-Aktie legt nach starken Q2-Zahlen zu/n | ||
| FIBROGEN | 8,250 | +2,61 % | FibroGen: Positive FDA-Signale für Anämie-Medikament beflügeln Aktie | ||
| SPERO THERAPEUTICS | 1,850 | 0,00 % | Spero Therapeutics, Inc.: Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 |
GALECTO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,47 % bei einem Aktienkurs von 3,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALECTO INC finden Sie auf Wallstreet Online.